



# SZABÁLYOZÓ T-SEJTEK HETEROGENITÁSÁBAN SZEREPET JÁTSZÓ HSPE1 VIZSGÁLATA EGY-SEJT TRANSZKRIPTOMIKAI MÓDSZERREL



**Kovács Árpád Ferenc<sup>1</sup>, Fekete Nóra<sup>1</sup>, Lumbach Réka<sup>1</sup>, Kőhidai László<sup>1</sup>, Buzás Edit<sup>1</sup>, Pállinger Éva<sup>1</sup>**


Semmelweis Egyetem, Genetikai, Sejt- és Immunbiológiai Intézet


2019/03/30


# A $T_{reg}$ -sejtek szerepe a humán reprodukcióban

## PERI-IMPLANTÁCIÓS IDŐSZAK










**T-SEJT AKTIVÁCIÓ**  
**TREG DIFFERENCIÁCIÓ POZITÍV SZABÁLYOZÁSA**  
**TREG PROLIFERÁCIÓ POZITÍV SZABÁLYOZÁSA**


# HIPOTÉZIS

NAÏVE T CELL

MEMORY REGULATORY T CELL




TROPHOBLAST-DERIVED EXTRACELLULAR VESICLES



## Analysing the role of HSPE1:

1.  $T_{reg}$  cell differentiation
2.  $T_{reg}$  cell heterogeneity

# MÓDSZEREK (1)



Intracellular  
HSPE1

PROTEIN: FLOW CYTOMETRY

mRNA: qPCR and

**SINGLE CELL TRANSCRIPTOMICS**

Extracellular  
vesicles

PROTEIN: ÁRAMLÁSI CITOMETRIA és  
TÖMEGSPEKTROMETRIA

miRNS: NGS

NUCLEUS

Chromosome 2: *HSPE1* gene

DNA: SEQUENCING

FUNKCIONÁLIS VIZSGÁLAT

SEJTMOZGÁS:  
HOLOMIKROSKÓP



CITOKINMINTÁZAT:  
ÁRAMLÁSI CITOMETRIA




↑ KNOCKOUT: RNP based CRISPR-Cas9 NLS



# MÓDSZEREK (2) EGY-SEJT TRANSZKRIPTOMIKA






mRNS expresszió




Azonosító

## 4. PBMC SEJTEK EGY-SEJT TRANSZKRIPTOMIKAI VIZSGÁLATA




louvain



CD4+ CD25+ Treg cells


louvain

UMAP2



UMAP1


- 0
- 1
- 2
- 3
- 4
- 5
- 6






CD4+ CD25+ Treg cells – RESTING TREGS

louvain



- 0
- 1
- 2
- 3
- 4
- 5
- 6












CD4+ CD25+ Treg cells – MEMORY TREGS




CD4+ CD45RA+ Naïve T cells




- 0
- 1
- 2
- 3
- 4
- 5
- 6





CD4+ CD45RA+ Naïve T cells




- 0
- 1
- 2
- 3
- 4
- 5
- 6




# Tnaive





# MARKER GENES




# MEMORY T cells




# CD4+ T cells



## CD4+ T CELLS






# EREDMÉNYEK

Naïve Treg

PBMC

UMAP2




UMAP1

- 0 Naïve CD4+ T cells
- 1 Memory CD4+ T cells
- 2 Effector CD4+ T cells
- 3 Effector CD8+ T cells
- 4 Naïve/CM CD8+ T cells
- 5 NK cells
- 6 B cells
- 7 CD14+ Monocytes
- 8 CD16+ Monocytes
- 9 pDC
- 10 \*
- 11 Naïve Treg cells
- 12 Plasmablast
- 13 mDC
- 14 **Memory Treg cells**



# EREDMÉNYEK

## Treg marker gének






TREG LINAGE DEFINING MARKER		TREG CHARACTERIZATION	
FOXP3		TREG SUBTYPES	
TREG MARKERS		<b>RESTING</b> TREGS (limited immunosuppressive capacity)	SELL (CD62L); CCR7 (CD197), FOXP1, BCL2, SATB1, HSPE1
CELL SURFACE	INTRACELLULAR		
IL2RA (CD25)	IKZF2	<b>EFFECTOR</b> TREGS	CTLA4 (CD152); TGFB1; PRDM1; PRF1, HSPE1, SQSTM1, LGALS1, ITGA4
ENTPD1 (CD39)	CAPG		
IL2RB (CD122)	CHCHD10		
TNFRSF4 (CD134)	WDR92	<b>TCR EARLY ACTIVATED</b> TREGS	NR4A1 (↓); EGR1; EGR2; MYC; DUSP2
CTLA4 (CD152)			
TNFRSF18 (CD357)		<b>ACTIVATED</b> TREGS	CD44; MKI67, <b>CTLA4</b> , <b>IL2RA</b> (VARIABLE EXPRESSION), CXCR3, S100A4, ITGB1, ITGAE, MKI67, SELL, SQSTM1, RNF26, HSPE1
GPR83			
IZUMO1R (JUNO)			
NEGATIVE MARKERS (OVEREXPRESSED IN CONVENTIONAL T CELLS)		<b>TCR ACTIVATED</b> TREGS	GATA3, ICOS, CTLA4, IL2RA, TNFRSF18, CD5
IL7R (CD127)	IGFBP4		
	DAPL1	<b>MEMORY</b> TREGS	CD27 (prevents apoptosis of Treg), CCR7 (↓), CTLA4, ICOS, BCL2, CD47; PRDM1, BCL6, CCR4, SQSTM1, RNF26, HSPE1
	THEMIS		
	ID2		
	SLC2A1 (effector T)	<b>POORLY SUPPRESSIVE RESTING</b> TREGS	FOXP3 (↓), SATB1, BACH2 (BOTH REPRESSORS OF THE EFFECTOR FUNCTIONS)


# EREDMÉNYEK

## HSPE1 expression in IL-6 stimulated human lymphocytes



Normalized to HPRT

## HSPE1 kifejeződés



1. Tömegspektrometriás és áramlási citometriás módszerrel kimutattuk a HSPE1 jelenlétét a BeWo trophoblaszterű sejtvonal-eredetű extracelluláris vezikulákban
2. A BeWo-eredetű EVk kötődtek a CD4+ T-sejtekhez és IL6RA downregulációt, valamint növekedett IL-10 szecernálást indukáltak
3. Hét különböző sejtklasztert azonosítottunk a Treg sejtpopulációban
4. Meghatároztunk 4 panelt a Treg sejt altípusok azonosítására
5. A Treg sejt altípusokban a HSPE1 klaszterfüggő expressziót mutat

A HSPE1+ BeWo-eredetű EVk indukáló faktorként szerepelhetnek a Treg sejtek differenciációjában és a memória Treg sejtek expansiójában

# KÖSZÖNETNYILVÁNÍTÁS

## FACS Team

**ÉVA PÁLLINGER**

Nóra Fekete

Borbála Bessenyei

Kornél Varga

*Kerpel-Fronius Ödön*

*Talent Support Program*

**GYÖRGY FEKETE**



## EV group

**EDIT BUZÁS**

Hargita Hegyesi

Tamás Visnovitz

Barbara Sódar

András Försönits

Szabina Mecsei

Anita Varga

Eszter Tóth

Krisztina Pálóczi

Sára Tóth

Viola Tamási

Krisztina Vukman

Katalin Szabó-Taylor

Márta Békés

1<sup>st</sup> Dept. of Obstetrics and  
Gynecology, Semelweis University

**JÁNOS RIGÓ**

Bálint Alasztics

Institut Imagine, Paris


**MICKÄEL MENAGÉR**

Marine Luka

Brieuc Perot



Ghaith Abdessalem







# 1. HSPE1 IMMUNOMODULÁLÓ HATÁSÁNAK A VIZSGÁLATA A REGULATORIKUS T-SEJT EXPANZIÓRA (ÚNKP-18-3-IV-SE-14)



# 1. HSPE1 IMMUNMODULÁLÓ HATÁSÁNAK A VIZSGÁLATA A REGULATORIKUS T-SEJT EXPANZIÓRA (ÚNKP-18-3-IV-SE-14)


## TRANSZFEKTÁLÁSI PROGRAM BEÁLLÍTÁSA ÉS OPTIMALIZÁLÁSA

Minta	Neofektor program	Transzfektációs hatékonyság (FACS - GFP)	Viabilitás (FACS - PI)	FACS mátrix	Fluoreszcens mikroszkóp
A1	CM-137	29%	84.7%		
A2	DS-150	41.6%	71.1%		
A3	CM-138	20.1%	81.4%		
A4	DS-120	16.6%	79.7%		
A5	CM-137	33.9%	81.6%		
A6	EN-100	54.8%	50%		
A7	CM-150	32.4%	80.3%		
A8	EN-100	23.7%	83.1%		
A9	DN-100	42.1%	72.9%		
A10	EN-138	62.5%	85.5%		
A11	DS-138	42.4%	73%		
A12	EN-150	66.9%	51.3%		
A13	DS-137	62.7%	67.5%		
A14	EN-113	49.4%	25.9%		
A15	DS-130	48.7%	71.9%		

EN-150 ÉS DS137


TRANSZFEKCIÓS HATÉKONYSÁG  
(FACS ÉS FLUORESZCENS MIKROSKÓP)

PI VIABILITÁS  
(FACS)





# 1. HSPE1 IMMUNMODULÁLÓ HATÁSÁNAK A VIZSGÁLATA A REGULATORIKUS T-SEJT EXPANZIÓRA (ÚNKP-18-3-IV-SE-14)




Indel → KO

## TRANSZFEKTÁLÁSI PROGRAM BEÁLLÍTÁSA ÉS OPTIMALIZÁLÁSA

3 TRANSZFEKCIÓS MÉDIUM: SF, SE ÉS SG  $\xrightarrow{\text{IRODALMI ADATOK BEÁLLÍTÁSI KÍSÉRLET}}$  SF


72 ÓRÁVAL A TRANSZFEKCIÓT KÖVETŐEN:



EN-150 + pMAX GFP



EN-150



pMAX GFP

# 1. HSPE1 IMMUNMODULÁLÓ HATÁSÁNAK A VIZSGÁLATA A REGULATORIKUS T-SEJT EXPANZIÓRA (ÚNKP-18-3-IV-SE-14)

## KLÓNSZELEKCIÓ

